Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a peptide boronic add drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz—(R)—Phe—(S)—Pro—(R)—Mpg—B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: Peptides which act as inhibitors or substrates of thrombin are provided.

Abstract: This invention is directed to peptide inhibitors of serine proteases, espcecially thrombin, in which the P1-P2 natural amide linkage is replaced by another bond. Exemplary thrombin inhibitors have the formula: X-(aa.sup.3)-(aa.sup.2)-.psi.-(aa.sup.1)-Z wherein X is H or a substituent on the N-terminal amino group, aa.sup.3 is a hydrophobic amino acid, aa.sup.23 is Pro, aa.sup.1 is Arg or an Arg analgoue, Z is --COOH or a heteroatom acid group and .psi. is a non-amide linkage.

Abstract: This invention provides peptides of the formula ##STR1## wherein X is H, CH.sub.3 or an N-protecting group;Y is(1) C.sub.3 -C.sub.9 alkyl optionally substituted by C.sub.1 -C.sub.4 alkoxy,(2) C.sub.5 -C.sub.10 aryl optionally substituted by C.sub.1 -C.sub.4 alkoxy,(3) C.sub.5 -C.sub.10 alkylaryl optionally substituted by C.sub.1 -C.sub.4 alkoxy,(4) (CH.sub.2).sub.n --Q or ##STR2## wherein Q is H, amino, amidino, imidizole, guanidino or isothioureido and n is 1-5;Z is COR.sub.1, ##STR3## wherein: R.sub.1 is H, OH, CH.sub.2 Cl, CH.sub.2 --CH.sub.2 --CO-pip, CF.sub.2 --CF.sub.2 --CO-pip, CH.sub.2 --CH(CH.sub.3)--CO-pip, CF.sub.2 --CF(CF.sub.3)--CO-pip, CH.sub.2 --CH.sub.2 --CO-Pro-NHEt, CF.sub.2 --CF.sub.2 --CO-Pro-NHEt or a chromophoric group,R.sub.2 and R.sub.3 may be the same or different and are selected from the group consisting of OH, OR.sub.6 and NR.sub.6 R.sub.7, wherein R.sub.6 and R.sub.7 may be the same or different and are selected from the group consisting of C.sub.1-10 alkyl, phenyl or C.sub.6 -C.

Abstract: Peptides which act as inhibitors or substrates of thrombin are derived from the formula: D-Phe-Pro-Arg or its analogues, wherein Phe is substituted by (a), wherein Ar.sub.1 or Ar.sub.2 are the same or different and are selected from the group consisting of phenyl, thienyl, pyridyl, naphthyl, thionaphtyl, indolyl and saturated groups corresponding to these, optionally substituted by up to three groups selected from C.sub.1 -C.sub.3 alkyl and C.sub.1 -C.sub.3 alkoxy, L.sub.1 and L.sub.2 are the same of different and are selected from the group consisting of CH.sub.2, C.sub.2 --C.sub.2, O-CH.sub.2, S-CH.sub.2, Ar-L taken together optionally means H, diphenyl-methyl, fluorenyl or saturated groups corresponding to these, but one of the Ar-L cannot be H when the other [CH.sub.2 ].sub.n -Q, (c) where Q=H, amino, amidino, imidazole, guanidino or isothioureido and n=1-5, preferably 3-5, or C.sub.3 -C.sub.9 alkyl and C.sub.5 -C.sub.